By Fortune Eromosele

Prof Sir Luis Emilio Abad one of the Top American and European Professor of Crown University Intl Chartered Inc.  Who doubles as America Grand Provost of Crown University Intl. Chartered Inc. and Representative of Vice Chancellor of Crown University in Argentina,  South America has been appointed as President of the ophthalmology session in the ELOS international congress in France.

It’s a great honor for him and His Excellency World Acclaimed Distinguished Professor Sir Bashiru Aremu and Crown University Intl Chartered Inc. with other various global universities and organizations worldwide to be the President of this International Scientists congress of the ophthalmology session in the ELOS international congress in France.

Prof Sir Luis Emilio Abad who is the Creator of devises and systems for ophthalmic surgery and intraocular microimplant for degenerative diseases of the retina – International Patents in Europe and USA who is also a Fellow of Cambridge Publishing in United Kingdom Dist. Prof. Sir Dr. (h.c.) Luis Emilio Abad has been bestowed with triple honors and awards that was approved to him by His Excellency UNESCO Laureate Prof Sir Bashiru Aremu. for his numerous achievement.

Read Also:

UNESCO Laureate Aremu approves multiple global awards for Sir George Gonzalez

UNESCO Laureate Prof Sir Bashiru Aremu applaud Prof Sir Luis Emilio Abad for his very interesting Title on the  : Intraocular Micro-implant Containing Tissue Plasminogen Activator (TPA).
That summary of this contained this following as stated below:
This intrascleral micro-implant with Tissue plasminogen activator (abbreviated tPA or PLAT), contains is a protein involved in the breakdown of blood clots. It is a serine protease (EC 3.4.21.68) found on endothelial cells, the cells that line the blood vessels.

As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Because it works on the clotting system, tPA (such as alteplase, reteplase, and tenecteplase) is used in clinical medicine is used to treat emboli, vitreous and/or retinal hemorrhages. 
tPA may be manufactured using recombinant biotechnology techniques. tPA created this way may be referred to as recombinant tissue plasminogen activator (rtPA).

This intraocular microimplant containing tPA is extremely important for treating severe retinal hemorrhages, preretinal and vitreous hemorrhages, the latter of which can cause vitreoretinal traction and retinal detachment due to traction.

Furthermore, His Excellency UNESCO Laureate, Prof Sir Bashiru Aremu advised him that he should not relax his efforts on promotion of International education and another activities.

Vanguard News Nigeria